Conference Cochairs:
Richard S. Finn, Geffen School of Medicine at UCLA, Santa Monica, CA
Josep M. Llovet, Icahn School of Medicine at Mount Sinai, New York, NY
Jessica Zucman-Rossi, Cordeliers Research Center at INSERM, Paris, France

THURSDAY, MAY 5, 2022

Registration
3:30 pm-7:30 pm

Welcome and Opening Remarks
6:30 pm-6:45 pm

Richard S. Finn, Geffen School of Medicine at UCLA, Santa Monica, CA
Josep M. Llovet, Icahn School of Medicine at Mount Sinai, New York, NY
Jessica Zucman-Rossi, Cordeliers Research Center at INSERM, Paris, France

Opening Keynote Lecture
6:45 pm-7:30 pm
Session Chair: Josep M. Llovet, Icahn School of Medicine at Mount Sinai, New York, NY

6:45-6:50 Introduction
Josep M. Llovet

6:50-7:30 Molecular drivers in hepatocellular carcinoma: The story of what we know and what are we missing
Jessica Zucman-Rossi, Cordeliers Research Center at INSERM, Paris, France

Opening Reception
7:30 pm-9:00 pm

FRIDAY, MAY 6, 2022

Continental Breakfast
7:00 am-8:00 am

Plenary Session 1: Molecular Pathogenesis of Hepatocellular Carcinoma
8:00 am-10:00 am
Session Chair: Jessica Zucman-Rossi, Cordeliers Research Center at INSERM, Paris, France

8:00-8:30  The good and the bad sides of tertiary lymphoid structures in liver cancer
Eli Pikarsky, The Hebrew University of Jerusalem, Jerusalem, Israel

8:30-9:00  Polyploidy, DNA damage response driver or gatekeeper of chronic liver diseases
Chantal Desdouets, Cordeliers Research Center at INSERM, Paris, France

9:00-9:30  Computational identification of targetable dependencies in hepatocellular carcinoma (HCC) associated with hepatitis B virus (HBV) replication*
Huat Chye Lim, University of California San Francisco, San Francisco, CA

9:30-10:00  PMEPA1 has an oncogenic role in the context of TGF-β signaling in hepatocellular carcinoma*
Marta Pique-Gili, Icahn School of Medicine at Mount Sinai, New York, NY

Break  10:00 am-10:30 am

Plenary Session 2: Inflammation and Liver Cancer
10:30 am-12:30 pm
Session Chair: Michael Karin, University of California at San Diego, La Jolla, CA

10:30-11:00  Metabolic control of HCC development
Michael Karin

11:00-11:30  Immune mechanisms driving carcinogenesis in NASH
Matthias Heikenwälder, German Cancer Research Center, Heidelberg, Germany

11:30-12:00  Mechanisms of immune escape in hepatocellular carcinoma
Amaia Lujambio, Icahn School of Medicine at Mount Sinai, New York, NY

12:00-12:15  Pretreatment immune cell composition and checkpoint ligand expression define the response to immunotherapy in advanced HCC: a study using single-cell sequencing*
Sarah Cappuyns, University Hospitals Leuven, Leuven, Belgium

12:15-12:30  CRISPR lipid nanoparticle modulates the tumor immune microenvironment of liver metastases by genetically eliminating M2 polarization pathway in macrophages*
Tyler Galbraith, Houston Methodist Research Institute, Houston, TX

Lunch on Own  12:30 pm-2:45 pm
Plenary Session 3: Risk Factors, Surveillance, and Molecular Detection
2:45 pm-4:45pm
Session Chair: Hashem B. El-Serag, Baylor College of Medicine, Houston, TX

2:45-3:15 Epidemiology and emerging risk factors in liver cancer
Hashem B. El-Serag

3:15-3:45 Surveillance for HCC in at-risk populations: Current perspectives and future directions
Amit Singal, UT Southwestern Medical Center, Dallas, TX

3:45-4:15 Role of liquid biopsy in early detection and assessment of response in HCC
Augusto Villanueva, Icahn School of Medicine at Mount Sinai, New York, NY

4:15-4:45 Molecularly-derived prognosis in HCC: truncal mutations vs acquired aberrations defining outcome
Jean-Charles Nault, INSERM, Paris, France

Poster Session / Reception
5:30 pm-7:30 pm

SATURDAY, MAY 7, 2022

Continental Breakfast
7:00 am-8:00 am

Plenary Session 4: Molecular Targeted Therapies in HCC
8:00 am-9:45 am
Session Chair: Josep M. Llovet, Icahn School of Medicine at Mount Sinai, New York, NY

8:00-8:30 Molecular targeted therapies for advanced HCC
Josep M. Llovet, Icahn School of Medicine at Mount Sinai, New York, NY

8:30-9:00 Prognostic and predictive biomarkers for cabozantinib in HCC
Lorenza Rimassa, Humanitas University, Rozzano, Italy

9:00-9:30 FDA perspective on accelerated and regular approvals in HCC and cholangiocarcinoma
Steven Lemery, U.S. Food and Drug Administration, Silver Spring, MD

9:30-9:45 A novel kinase inhibitor for B-catenin mutant hepatocellular carcinoma*
Alexander Rialdi, Icahn School of Medicine at Mount Sinai, New York, NY
Break 9:45 am-10:15 am

Plenary Session 5: Trial Design and Endpoints in HCC
10:15 am-12:15 pm
*Session Chair: Josep M. Llovet, Icahn School of Medicine at Mount Sinai, New York, NY*

- 10:15-10:45 Lessons learnt from phase III trials in HCC: OS, PFS and ORR
  Andrew X. Zhu, Massachusetts General Hospital, Boston, MA
- 10:45-11:15 Trial design and endpoint definition in intermediate stage HCC: A challenge
  Peter R. Galle, University Medical Center Mainz, Mainz, Germany
- 11:15-11:45 Trial enrichment and proof of concept studies
  Augusto Villanueva, Icahn School of Medicine at Mount Sinai, New York
- 11:45-12:15 pm Assessing response and time-to-event end-points: RECIST and mRECIST
  Riccardo Lencioni, University of Pisa, Pisa, Italy

Lunch on Own 12:15 pm-2:15 pm

Plenary Session 6: Immunotherapies in HCC: Molecular Mechanisms and Combination Regimens
2:15 pm-3:45 pm
*Session Chair: Richard S. Finn, Geffen School of Medicine at UCLA, Santa Monica, CA*

- 2:15-2:45 Immune checkpoint inhibitors and NAFLD
  Mark Yarchoan, Johns Hopkins University, Baltimore, MD
- 2:45-3:15 Impact of single checkpoint inhibitors and biomarkers of response
  Anthony El-Khoueiry, USC Norris Comprehensive Cancer Center, Los Angeles, CA
- 3:15-3:45 Combination therapies including checkpoint inhibitors in HCC: The dawn of a new era
  Richard S. Finn, Geffen School of Medicine at UCLA, Santa Monica, CA

Break 3:45 pm-4:15 pm

Plenary Session 7: Molecular Pathogenesis and Drivers of Cholangiocarcinoma
4:15 pm-6:00 pm
Session Chair: Ghassan K. Abou-Alfa, Memorial Sloan Kettering Cancer Center, New York, NY

4:15-4:45 Molecular pathogenesis and cell of origin of intrahepatic cholangiocarcinoma (iCCA)
Sumera Ilyas, Mayo Clinic, Rochester, MN

4:45-5:15 Molecular classes and landscape of drivers of iCCA and eCCA
Daniela Sia, Icahn School of Medicine at Mount Sinai, New York, NY

5:15-5:45 Dissecting molecular differences between iCCA and eCCA
Xin Wei Wang, National Cancer Institute, Bethesda, MD

5:45-6:00 Identifying regulatory transcription factors in primary liver cancer cell lineage commitment using single cell ATAC sequencing
Amanda J. Craig, National Cancer Institute, Bethesda, MD

Evening on own

SUNDAY, MAY 8, 2022

Continental Breakfast
7:00 am-8:00 am

Plenary Session 8: Molecular Targeted Therapies and Precision Oncology in iCCA
8:00 am-10:00 am
Session Chair: Juan Valle, University of Manchester, Manchester, England

8:00-8:30 IDH Inhibitors: Rationale, molecular mechanisms and benefit
Andrew X. Zhu, Massachusetts General Hospital, Boston, MA

8:30-9:00 Clinical trials and molecular therapies in iCCA
Juan Valle

9:00-9:30 FGFR2 fusion inhibitors: Clinical benefit and mechanisms of resistance
Mitesh Borad, Mayo Clinic, Scottsdale, Arizona

9:30-10:00 Trial Design in the era of precision oncology and combination therapies
John Bridgewater, University College London, London, England

Break 10:00 am-10:30 am
Plenary Session 9: Molecular Pathogenesis and Treatment of Hepatoblastoma
10:30 am-11:30 am

*Session Chair: Dolores H. Lopez-Terrada, Texas Children’s Hospital, Houston, TX*

10:30-11:00  
**Advances in the pathogenesis and classification of pediatric hepatocellular neoplasms**
Dolores H. Lopez-Terrada

11:00-11:30  
**Present and future of precision oncology in hepatoblastoma**
Carolina Armengol, Germans Trias i Pujol Research Institute-Barcelona

Closing Keynote Lecture
11:30 am-12:30 pm

*Session Chair: Josep M. Llovet, Icahn School of Medicine at Mount Sinai, New York, NY*

11:30-11:40  
Introduction
Josep M. Llovet, Icahn School of Medicine at Mount Sinai, New York, NY

11:40-12:30  
**Present and future of pathogenesis and molecular treatment of iCCA**
Ghassan K. Abou-Alfa, Memorial Sloan Kettering Cancer Center, New York, NY

Closing Remarks
12:30 pm

Richard S. Finn, Geffen School of Medicine at UCLA, Santa Monica, CA
Josep M. Llovet, Icahn School of Medicine at Mount Sinai, New York, NY
Jessica Zucman-Rossi, Cordeliers Research Center at INSERM, Paris, France

*Short talk from proffered abstract*